Clinical Features and Risk Factors of Active Tuberculosis in Patients with Behçet’s Disease

Table 2

Clinical presentation and laboratory results of BD patients with and without ATB.

	BD with ATB ()	BD without ATB ()
Systemic involvement of BD
Oral ulceration (%)	19 (90.5%)	68 (98.6%)	0.135
Genital ulceration (%)	18 (85.7%)	49 (71.0%)	0.176
Erythema nodosa (%)	12 (57.1%)	30 (43.5%)	0.272
Ocular lesions (%)	4 (19.0%)	25 (36.2%)	0.140
Vascular manifestations (%)	4 (19.0%)	25 (36.2%)	0.140
Gastrointestinal involvement (%)	6 (28.6%)	24 (34.8%)	0.597
CNS involvement (%)	3 (14.3%)	15 (21.7%)	0.548
Symptoms related to TB infection
Fever (%)	18 (85.7%)	34 (49.3%)	0.003
Cough (%)	8 (38.1%)	5 (7.2%)	0.002
Expectoration (%)	7 (33.3%)	3 (4.3%)	0.001
Night sweating (%)	8 (38.1%)	4 (5.8%)	0.001
Weight loss (%)	13 (61.9%)	28 (40.6%)	0.086
Laboratory tests
ESR (mm/h, median, IQR)	31 (22, 57)	16 (6, 39)	0.004
hsCRP (mg/L, median, IQR)	28.32 (8.50, 63.83)	10.37 (1.61, 43.59)	0.038
IgG (g/L, median, IQR)	12.55 (9.98,15.61)	9.6 (7.84,13.13)	0.006
IgA (g/L, median, IQR)	2.78 (1.75, 3.66)	2.28 (1.59, 3.04)	0.286
IgM (g/L, median, IQR)	0.91 (0.71, 1.74)	0.93 (0.71, 1.33)	0.575
Positive T-SPOT.TB (%)	17 (80.95%) ()	19 (27.54%) ()	0.000
T-SPOT.TB value (SFC/10^6PBMC, median, IQR)	336 (92, 1084)	0 (0, 27)	0.000

ESR: erythrocyte sedimentation rate; hsCRP: hypersensitive C reactive protein; IgG: immunoglobulin G; IgA: immunoglobulin A; IgM: immunoglobulin M; SFC: spot-forming cells; PBMC: peripheral blood mononuclear cells.